NASDAQ:IMCC IM Cannabis Q3 2025 Earnings Report $0.24 +0.00 (+1.28%) As of 01:52 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast IM Cannabis EPS ResultsActual EPS-$0.54Consensus EPS -$0.02Beat/MissMissed by -$0.52One Year Ago EPSN/AIM Cannabis Revenue ResultsActual Revenue$9.89 millionExpected Revenue$14.27 millionBeat/MissMissed by -$4.38 millionYoY Revenue GrowthN/AIM Cannabis Announcement DetailsQuarterQ3 2025Date11/13/2025TimeBefore Market OpensConference Call DateThursday, November 13, 2025Conference Call Time9:00AM ETConference Call ResourcesPress Release (6-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(6-K) IM Cannabis Earnings HeadlinesIM Cannabis Corp. Announces First Quarter 2026 Financial ResultsMay 13, 2026 | prnewswire.comIM Cannabis Raised US$550,000 of Gross Proceeds in Convertible Note FinancingsMay 7, 2026 | prnewswire.comSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billion - you'd be buying at $1.75 trillion. But one small, publicly traded company sits directly in SpaceX's path, still priced like Wall Street hasn't noticed. It powers the infrastructure Musk's operation can't run without. Dylan Jovine is naming the ticker free - before the June S-1 closes the window.May 22 at 1:00 AM | Behind the Markets (Ad)IMC Announces Receipt of Nasdaq Minimum Bid Price NotificationApril 10, 2026 | prnewswire.comIM Cannabis Reports 2025 Results: Revenue of C$54.7 Million with Over 134% Growth in Germany and Positive Operating Cash FlowMarch 31, 2026 | prnewswire.comIMC Announces a Strategic Entry to the Cyber Drone Interception and Satellite Intelligence Markets by Signing a Non-Binding Agreement to Acquire 51% of Blackaxe TechnologiesMarch 17, 2026 | prnewswire.comSee More IM Cannabis Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like IM Cannabis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on IM Cannabis and other key companies, straight to your email. Email Address About IM CannabisIM Cannabis (NASDAQ:IMCC) Corp is a vertically integrated medical cannabis company based in Israel, specializing in the research, cultivation and production of cannabis-based formulations. The company holds three key licenses granted by the Israeli Ministry of Health, covering cultivation, possession and distribution of medical-grade cannabis. Its production facilities in Moshav Yizrael feature controlled-environment agriculture chambers designed to deliver consistent, high-purity cannabinoid profiles. The company’s product portfolio includes standardized cannabis oils, distillates, vaporizer cartridges and topical preparations, all formulated under Good Manufacturing Practice (GMP) standards. IM Cannabis invests in ongoing scientific research and development to advance proprietary extraction techniques and novel dosage forms, with an emphasis on patient safety, reproducibility and therapeutic efficacy. These efforts support both internal clinical initiatives and potential collaborations with academic and pharmaceutical partners. Since its founding in 2018, IM Cannabis has pursued domestic and international market expansion through supply agreements and export licenses. The company serves Israel’s growing medical cannabis patient base and has secured partnerships to facilitate exports to regulated markets, including Europe and Australia. IM Cannabis is led by an experienced management team with backgrounds in pharmaceutical development, agriculture technology and regulatory affairs, and trades on the Nasdaq Capital Market under the ticker IMCC.View IM Cannabis ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Overextended, e.l.f. Beauty Is Primed to Rebound in Back HalfDeere Beats Q2 Estimates, But Ag Weakness Weighs on OutlookNVIDIA Price Pullback? Don’t Count on It, Business Is AcceleratingMeta Platforms 10% Layoff Raises a Bigger Question About AI SpendingBiogen Stock Slides After Trial Miss, But Analysts Stay BullishTarget Shows Strengths, But Analysts Want to See MoreLowe's Finds Support at $215 After Q1 Earnings Sell-Off Upcoming Earnings AutoZone (5/26/2026)Marvell Technology (5/27/2026)PDD (5/27/2026)Synopsys (5/27/2026)Bank Of Montreal (5/27/2026)Bank of Nova Scotia (5/27/2026)Salesforce (5/27/2026)Snowflake (5/27/2026)Autodesk (5/28/2026)Costco Wholesale (5/28/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
